{"ticker":"PBYI","name":"Puma Biotechnology Inc","sector":"Biotech / Pharma","total_score":56.47,"grade":"C","components":{"insider_buy":0.0,"publication":1.0,"dilution_risk":0.26,"clinical_trial":1.0,"short_interest":0.5},"calculated_at":"2026-10-02 07:00:04.273566","latest_signals":[{"signal_type":"clinical_trial","score":0.9700000000000001,"data":{"as_of":"2026-09-30","total":11,"phase1":3,"phase2":9,"phase3":0,"phase4":0,"source_type":"clinicaltrials.gov","source_url":"https://clinicaltrials.gov/","public_gate":"fresh_clinicaltrials_aggregate"},"created_at":"2026-09-30 03:30:07.686188"},{"signal_type":"dilution_risk","score":0.26,"data":{"float_risk":30,"risk_level":"MEDIUM","cash_runway":0,"description":"Dilution score: 26/100 (MEDIUM), cash runway not available","months_cash":null,"warrant_risk":40,"dilution_score":26,"convertible_risk":40,"offering_ability":40,"public_risk_label":"MEDIUM","score_limitations":[],"shares_outstanding":null,"outstanding_warrants":0.0,"source_type":"DilutionWatch SEC-derived score","source_url":"https://www.sec.gov/edgar/search/","public_gate":"fresh_dilutionwatch_score"},"created_at":"2026-10-01 18:13:37.176076"},{"signal_type":"publication","score":1.0,"data":{"description":"5 linked PubMed record(s) matched the source query.","search_term":"Puma","recent_articles":[{"url":"https://pubmed.ncbi.nlm.nih.gov/42717134/","pmid":"42717134","title":"Diffusion histogram analysis predicts progression-free survival in contrast enhancing recurrent IDH mutant gliomas treated with bevacizumab.","source":"J Neurooncol","authors":"Loxterkamp E","pubdate":"2026 Sep 9"},{"url":"https://pubmed.ncbi.nlm.nih.gov/42699353/","pmid":"42699353","title":"pH- and ROS-Responsive Polyurethane/Polylysine Nanomicelles Delivering Leonurine Attenuate Inflammation and Cartilage Damage in Experimental Rheumatoid Arthritis.","source":"Int J Nanomedicine","authors":"Bai L","pubdate":"2026"},{"url":"https://pubmed.ncbi.nlm.nih.gov/42649154/","pmid":"42649154","title":"Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial.","source":"Nat Commun","authors":"David S","pubdate":"2026 Jul 27"},{"url":"https://pubmed.ncbi.nlm.nih.gov/42647116/","pmid":"42647116","title":"A Phase Ib/II Study of Atezolizumab in Combination with Thiopurine Therapy in Patients with Metastatic Solid Tumors and Intermediate Tumor Mutational Burden.","source":"Cancer Res Commun","authors":"Secher CF","pubdate":"2026 Sep 1"},{"url":"https://pubmed.ncbi.nlm.nih.gov/42636838/","pmid":"42636838","title":"Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial.","source":"Lancet Oncol","authors":"Lara González LE","pubdate":"2026 Sep"}],"total_publications":5,"source_type":"PubMed","source_url":"https://pubmed.ncbi.nlm.nih.gov/","public_gate":"linkable_pubmed_article_required"},"created_at":"2026-09-23 05:05:57.867693"},{"signal_type":"short_interest","score":0.5,"data":{"trend":"STABLE","change_pct":1.06,"description":"Short interest: 11.05% of float, squeeze risk: MODERATE","squeeze_risk":"MODERATE","days_to_cover":13.8,"short_interest":4319663,"short_pct_float":11.05,"source_type":"FINRA short interest","source_url":"https://www.finra.org/finra-data/browse-catalog/equity-short-interest/data","public_gate":"fresh_finra_short_interest"},"created_at":"2026-10-01 18:33:57.766823"}],"signal_counts":{"clinical_trial":1,"dilution_risk":1,"publication":1,"short_interest":30},"ticker_status":null}